Oya Yonal

Oya Yonal

Auto-generated profile, based on publicly available information

Oya Yonal

Department of Gastroenterology, Marmara University Faculty of Medicine, Istanbul, Turkey.

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012
Verified
Journal Article
Closed access
Yusuf YilmazYusuf Yilmaz
Yusuf Yilmaz
OYOya Yonal
Oya Yonal
ODOguzhan Deyneli
Oguzhan Deyneli
CCCigdem Ataizi Celikel
Cigdem Ataizi Celikel
CKCem Kalayci
Cem Kalayci
DDDeniz Guney Duman
Deniz Guney Duman

16 November 2010 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
Yusuf YilmazYusuf Yilmaz
Yusuf Yilmaz
OYOya Yonal
Oya Yonal
FEFatih Eren
Fatih Eren
RKRamazan Kurt
Ramazan Kurt
CCCigdem Ataizi Celikel
Cigdem Ataizi Celikel
EAErol Avsar
Erol Avsar
Background: Evidence suggests that zinc-α2-glycoprotein (ZAG) might serve as a biomarker for human metabolic alterations. We measured serum ZAG in patients with non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of the metabolic syndrome, and examined its association with clinical, biochemical, and histological phenotypes. Methods: Serum ZAG was determined using ELISA in 90 patients with biopsy-proven NAFLD and 81 controls. Results: Serum ZAG concentrations did not differ in patients with NAFLD (median 61 μg/mL; interquartile range: 56–73 μg/mL) compared with healthy controls (median 66 μg/mL; interquartile range: 56–78 μg/mL, Mann-Whitney U-test, p=NS). However, among patients with NAFLD serum ZAG concentrations were significantly higher in males and in those with the metabolic syndrome. After stepwise linear regression analysis, serum ZAG concentrations were the only independent predictor of the number of metabolic syndrome components in patients with NAFLD (β=0.22; t=2.001, p<0.05). Conclusions: In summary, the hypothesis of an association between NAFLD and serum ZAG concentrations is not supported by the present results. However, ZAG remains an interesting molecule for further research in the field of human metabolic disorders.

25 June 2013 in Case Reports in Gastroenterology
Verified
Journal Article
Open access
PDF file
OYOya Yonal
Oya Yonal
DIDuygu Ibrisim
Duygu Ibrisim
YSYıldıran Songur
Yıldıran Songur
YCYılmaz Cakaloglu
Yılmaz Cakaloglu
KTKoray Tuncer
Koray Tuncer
SOSadakat Ozdil
Sadakat Ozdil
Primary malignant melanoma of the esophagus (PMME) comprises only 0.1-0.2% of all malignant esophageal tumors. PMME tumors are highly aggressive and metastasize early via hematogenic and lymphatic pathways. Treatment outcome is poor because the cancer has often advanced at the time of diagnosis. Inoperability, unsuccessful treatment with radiotherapy and chemotherapy in advanced tumors and metastases have contributed to its poor prognosis. Here, we present the endoscopic features, endoscopic ultrasonography findings and management of a PMME case.

15 December 2014 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
OYOya Yonal
Oya Yonal
FEFatih Eren
Fatih Eren
Yusuf YilmazYusuf Yilmaz
Yusuf Yilmaz
ÖAÖzlen Atuğ
Özlen Atuğ
HÖHülya Hamzaoğlu Över
Hülya Hamzaoğlu Över
Background/Aims: The endocannabinoid system can exert beneficial effects on gastrointestinal inflammation, and cannabinoid receptor-2 (CB2) agonists may represent a new therapeutic approach in inflammatory bowel disease (IBD). A functional CB2 Q63R polymorphism (rs35761398) in the CNR2 gene has been shown to affect the immunomodulating properties of the CB2 receptor. We sought to investigate whether the functional CB2 Q63R polymorphism (rs35761398) is associated with IBD susceptibility in a Turkish clinical sample. Materials and Methods: A total of 202 IBD patients, comprising 101 Crohn’s disease (CD) patients and 101 ulcerative colitis (UC) patients, and 101 healthy controls were included in the study. The CB2 Q63R polymorphism was genotyped using real-time PCR. Results: There were no significant differences in the genotype frequencies of the three study groups. The odds ratio of the minor Q allele for CD relative to the common R allele was not significant (OR =1.02, 95% CI =0.67-1.56, p=0.99). Similarly, the odds ratio of the minor Q allele for UC relative to the common R allele did not reach statistical significance (OR =1.10, 95% CI =0.72-1.68, p=0.75). Moreover, the genotype frequencies did not show any significant association with the disease extent in either CD (p= 0.71) or UC patients (p=0.59). Conclusion: These pilot findings suggest that CB2 Q63R polymorphism does not play a major role in genetic susceptibility to IBD or in its disease phenotypes among Turkish subjects.

1 April 2009
Verified
Journal Article
Closed access
Yusuf YilmazYusuf Yilmaz
Yusuf Yilmaz
OAOzlen Atug
Ozlen Atug
OYOya Yonal
Oya Yonal
DDDeniz Duman
Deniz Duman
OOOsman Ozdogan
Osman Ozdogan
CKCem Kalayci
Cem Kalayci

30 September 2010 in Metabolism
Verified
Journal Article
Closed access
Yusuf YilmazYusuf Yilmaz
Yusuf Yilmaz
YAYesim Ozen Alahdab
Yesim Ozen Alahdab
OYOya Yonal
Oya Yonal
NINese Imeryuz
Nese Imeryuz
CKCem Kalayci
Cem Kalayci